54 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 54 of 54 clinical reviews.
A clinical guide to dutasteride (Avodart) use after bariatric surgery, covering altered pharmacokinetics, absorption concerns, dosing strategies, and hair-loss treatment evidence in post-bariatric patients.
Evidence-based guide to dutasteride 0.5 mg dosing in adults aged 65 and older, covering pharmacokinetics, BPH efficacy, renal considerations, drug interactions, and deprescribing.
A clinical guide to dutasteride (Avodart) monitoring in adults 65 and older, covering falls risk, renal considerations, drug interactions, PSA interpretation, and deprescribing thresholds.
A guide to dutasteride (Avodart) monitoring protocols for men and women aged 50 to 64, covering PSA interpretation, cardiovascular checks, hormone interactions, and safety labs at each follow-up visit.
A guide to dutasteride's off-label applications beyond BPH, including androgenetic alopecia, hirsutism, and prostate cancer chemoprevention, with evidence grades and cited clinical trials.
A clinician-level review of dutasteride (Avodart) regulatory approvals across the US, EU, Canada, and UK, including BPH indications, off-label hair loss use, and key differences between jurisdictions.
A guide to dutasteride (Avodart) safety in adults aged 30, 49, covering sexual side effects, cardiovascular signals, cancer risk, drug interactions, and how to weigh risks against benefits for BPH and hair loss.
A guide to dutasteride safety in young adults ages 18, 29, covering sexual side effects, fertility, mental health signals, contraindications, and monitoring protocols with primary-source citations.
Complete dutasteride dosing guide for adults aged 30-49, covering FDA-approved BPH doses, off-label hair loss use, clinical trial data, and practical management tips for men in their peak working years.
Does dutasteride (Avodart) change appetite or food cravings? A deep dive into the pharmacology, clinical trial data, and patient reports around dutasteride and appetite.
A clinician-level review of dutasteride (Avodart) and autoimmune disease: drug-induced lupus risk, thyroid interactions, immunomodulatory mechanisms, dosing cautions, and how to monitor patients with pre-existing autoimmune conditions.
A comprehensive clinical review of how dutasteride (Avodart) affects bone mineral density, fracture risk, and skeletal health in men with BPH and androgenetic alopecia. Includes trial data, mechanisms, and monitoring guidance.
A deep dive into dutasteride (Avodart) and long-term cardiovascular risk, covering the REDUCE trial, PCPT-era data, MACE signals, lipid effects, and current prescribing guidance for men on 5-alpha-reductase inhibitor therapy.
An evidence-based look at dutasteride (Avodart) and cognitive function, covering neurosteroid pathways, clinical trial data, risk stratification, and what patients should discuss with their prescribers.
Compare the cost of dutasteride (Avodart) against finasteride, tamsulosin, and combination therapies for BPH and hair loss. Includes generic pricing, insurance coverage, and clinical value analysis.
A clinician-level review of dutasteride (Avodart) dosing in renal impairment, covering pharmacokinetics, mechanism of action, trial data, and practical prescribing guidance.
A guide to dutasteride (Avodart) safety in men aged 65 and older, covering renal function, falls risk, drug interactions, cardiovascular signals, and deprescribing criteria.
What oral dutasteride evidence really shows for male pattern hair loss, what it does not establish about dry skin or sebum, and how its long half-life, sexual effects, fertility, pregnancy-exposure, and PSA warnings change the decision.
A clinical history of dutasteride (Avodart), from GSK's dual 5-alpha reductase inhibitor development through FDA approval for BPH and its off-label rise in androgenetic alopecia treatment.
Avodart (dutasteride) info for ages 50-64: half-life, DHT suppression, REDUCE trial prostate cancer data, sexual side effects, and drug interaction risks.
A clinical review of dutasteride (Avodart) manufacturing, GSK production history, soft gelatin capsule supply challenges, generic market entry, and documented shortage events.
A deep dive into dutasteride (Avodart) and its effects on mood, depression, anxiety, libido, and cognitive function, with primary-literature citations and clinical guidance.
A deep dive into how dutasteride (Avodart) is metabolized, how it affects androgen-driven thermogenesis, and what clinicians and patients need to know about energy expenditure changes on long-term therapy.
A clinician-level review of dutasteride (Avodart) and muscle preservation strategies, covering DHT suppression, resistance training protocols, protein targets, and monitoring guidance backed by primary-source evidence.
A detailed look at dutasteride (Avodart) patent expiry dates, Paragraph IV challenges, generic approvals, and what the post-exclusivity market means for BPH and hair loss patients.
A clinical deep-dive into dutasteride (Avodart) pharmacokinetics covering absorption, distribution, metabolism, elimination, its 5-week half-life, CYP3A4 metabolism, and DHT suppression kinetics.
Board-reviewed guide on the dutasteride (Avodart) pre-surgery hold window: when to stop, why it matters for PSA, bleeding, and anesthesia, and how to safely restart.
What happens when you stop dutasteride during illness, when it's safe to restart, and exactly how to resume therapy after acute illness. guidance with primary-literature citations.
A clinician-level review of how dutasteride (Avodart) affects sleep architecture, including neurosteroid suppression, REM disruption, and clinical management strategies backed by primary literature.
Complete guide to dutasteride (Avodart) storage conditions, shelf-life data, chemical stability, and what happens when capsules are exposed to heat, moisture, or light, with PubMed and FDA citations.
Board-reviewed clinical guide to dutasteride (Avodart) travel protocols, timezone-shift dosing, storage rules, and what to do when doses are missed mid-journey.
A week-by-week guide to the first 30 days on dutasteride (Avodart) for BPH and hair loss. Covers DHT suppression timelines, shedding phases, side effects, and what your lab work should show.
A guide to dutasteride (Avodart) monitoring for men aged 18 to 29, covering labs, fertility, sexual side effects, PSA interpretation, and when to stop treatment.
Find out whether Cigna covers Avodart (dutasteride) for BPH and hair loss, what prior-authorization criteria apply, how step therapy works, and how to appeal a denial.
State Medicaid coverage for Avodart (dutasteride) varies widely. Learn formulary status, prior authorization requirements, step therapy rules, and how to appeal a denial.
TRICARE covers generic dutasteride on its formulary for BPH, but brand-name Avodart may require prior authorization. Learn about formulary tiers, step therapy, appeal processes, and cost-saving strategies for military beneficiaries.
UnitedHealthcare typically covers Avodart (dutasteride) on Tier 3 with prior authorization for BPH. Learn formulary placement, PA criteria, step therapy rules, appeal steps, and cost-saving alternatives.
Evidence-based guide to dutasteride pharmacokinetics, CYP3A4 metabolism, and dose considerations in patients with liver disease. Includes FDA label gaps, clinical reasoning, and monitoring strategies.
Evidence-based guide to dutasteride food and supplement interactions, including saw palmetto, St. John's wort, grapefruit, and fat-soluble vitamin concerns.
A clinician-level review of dutasteride pipeline developments, novel delivery systems, combination therapies, and emerging indications beyond BPH and androgenetic alopecia.
Evidence-based guide to prescribing dutasteride in transplant recipients, people living with HIV, patients with hepatic or renal impairment, and other special populations. Includes drug interactions, dose adjustments, and monitoring protocols.
Evidence-based guide to handling a missed dose of dutasteride (Avodart). Covers pharmacokinetics, the 5-week half-life advantage, clinical impact, and step-by-step instructions.
Evidence-based monitoring guide for dutasteride (Avodart) in adults aged 30-49, covering PSA adjustments, liver function, hormonal panels, and safety labs for BPH and hair loss.
Evidence-based monitoring schedule for dutasteride (Avodart), including baseline labs, PSA adjustments, liver function testing, and follow-up exam intervals for BPH and hair loss.
Evidence-based guide to managing dutasteride (Avodart) overdose or accidental double dosing, including pharmacokinetic data, clinical safety margins, and when to seek emergency care.
Dutasteride (Avodart) is FDA Pregnancy Category X. This article covers teratogenic risk, blood donation restrictions, partner exposure precautions, lactation data, and clinical guidance for 5-alpha reductase inhibitor use near conception.
A clinician-grade review of dutasteride (Avodart) safety signals, FDA label changes, the REDUCE trial prostate cancer finding, sexual adverse effects, and mental health concerns, with PubMed-cited evidence.
A guide to how dutasteride works, its oral dosing for BPH and hair loss, why no injectable form exists, and what the clinical evidence says about efficacy and safety.
Dutasteride's half-life is 5 weeks at steady state, the longest of any 5-alpha reductase inhibitor. FDA dose is 0.5 mg daily, no age adjustment needed.
Dutasteride interacts most with strong CYP3A4 inhibitors like ketoconazole, raising its levels 2.5-fold. No clinically significant effect on warfarin or digoxin.
A physician-level explanation of how dutasteride (Avodart) works, covering dual 5-alpha reductase inhibition, DHT suppression kinetics, tissue-level effects in prostate and scalp, and how its pharmacology compares to finasteride.
A clinical deep-dive into how CYP3A4, SRD5A1, SRD5A2, and androgen receptor gene polymorphisms influence dutasteride metabolism, efficacy, and side-effect risk.
Stopping dutasteride: what to record about urinary symptoms, PSA, hair changes and sexual effects, plus the six-month blood donation wait.
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.